Predict who benefits after infusion
- Trial ID
- NCT06080399
- Official Title
- Could Psycho-bio-social Context and Personality be a Predictive Factor of Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease Patients? - PERSO-PERF Study
- Goal
- Predict who benefits after infusion
- Status
- RECRUITING
- Sponsor
- University Hospital, Toulouse
- Study Type
- OBSERVATIONAL
- Enrollment
- 70 participants
- Conditions
- Parkinson Disease
- Interventions
- Continuous subcutaneous apomorphine infusion (CSAI)
Plain-Language Summary
The goal is to find out whether a person’s personality, psychological and social situation, plus biological factors, predict who will have a real improvement in quality of life after starting continuous subcutaneous apomorphine infusion. Apomorphine is a fast-acting dopamine agonist given continuously under the skin to provide steadier stimulation of dopamine receptors, often smoothing levodopa on/off swings and reducing off time; the study simply follows patients starting CSAI as part of usual care while measuring mood, personality, social supports and medical factors. They are enrolling people about 40 to 75 years old with Parkinson’s by UKPDSBB criteria who have motor fluctuations or disabling dyskinesia and are awaiting CSAI, excluding those with atypical parkinsonism, prior deep brain stimulation, certain psychiatric disorders, MoCA under 24, major medical problems, or legal guardianship.
Locations
- Chu de Lyon, Bron, France
- Hopital Gabriel Montpied, Clermont-Ferrand, France
- Chu de Grenoble, Grenoble, France
- Chu Limoges, Limoges, France
- Chu de Nancy, Nancy, France
- Chu de Nice, Nice, France
- Chu de Poitiers, Poitiers, France
- Chu de Rennes, Rennes, France
- Chu de Rouen, Rouen, France
- Chu de Toulouse, Toulouse, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Continuous subcutaneous apomorphine infusion (CSAI). The goal is to find out whether a person’s personality, psychological and social situation, plus biological factors, predict who will have a real improvement in quality of life after starting continuous subcutaneous apomorphine infusion. Apomorphine is a fast-acting dopamine agonist given continuously under the skin to provide steadier stimulation of dopamine receptors, often smoothing levodopa on/off swings and reducing off time; the study simply follows patients starting CSAI as part of usual care while measuring mood, personality, social supports and medical factors. They are enrolling people about 40 to 75 years old with Parkinson’s by UKPDSBB criteria who have motor fluctuations or disabling dyskinesia and are awaiting CSAI, excluding those with atypical parkinsonism, prior deep brain stimulation, certain psychiatric disorders, MoCA under 24, major medical problems, or legal guardianship.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 10 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 1 month.